Comorbidities of atopic dermatitis—what does the evidence say? - 04/05/23
Abstract |
Atopic dermatitis (AD) is a common disease that is associated with atopic and nonatopic comorbidities. There has been a growing interest in this area of AD, because presence or risk of comorbidities can in many ways impact the management of patients with AD. Thus, some treatments for AD may improve its comorbidities as well, whereas others may increase their risk. In this review article, we discuss various comorbidities of AD mostly on the basis of the results of recent multiple systematic reviews and meta-analyses to update readers about this rapidly developing area of dermatology. We emphasize the important information provided by studies presenting both relative risk and absolute risk, and show that AD is associated with, among others, atopic comorbidities such as asthma, rhinitis, and food allergy, nonatopic comorbidities such as ocular, psychiatric, infectious, endocrine, autoimmune, and cardiovascular diseases, and certain cancers. Clinicians need to be aware of these and be cognizant about positive and negative effects of existing and new treatments for AD.
Il testo completo di questo articolo è disponibile in PDF.Key words : Atopic dermatitis, atopy, asthma, burden, comorbidity, epidemiology
Abbreviations used : AA, AD, AR, CCI, CVD, IBD, JAK, MOF, RA, SR
Mappa
J.P.T. is supported by an unrestricted grant from the Lundbeck Foundation. |
|
Disclosure of potential conflict of interest: J. P. Thyssen is an advisor for AbbVie, Almirall, Arena Pharmaceuticals, Coloplast, OM Pharma, Aslan Pharmaceuticals, Union Therapeutics, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; a speaker for AbbVie, Almirall, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; and received research grants from Pfizer, Regeneron, and Sanofi-Genzyme. A.-S. Halling is a speaker for LEO Pharma and consultant for Coloplast A/S. P. Schmid-Grendelmeier received speaker and consultancy fees from AbbVie, ALK Abello, AstraZeneca, Biomed, Galderma, GlaxoSmithKline, LEO Pharma, Eli Lilly & Co, L’Oréal, Novartis, Pfizer, Pierre Fabre, Roche Pharma, Roche-Posay, Sanofi-Genzyme, Stallergenes, and Thermo Fisher. J. I. Silverberg is a speaker for AbbVie, Eli Lilly & Co, LEO Pharma, Pfizer, Regeneron, and Sanofi-Genzyme; received honoraria as a consultant and/or advisory board member for AbbVie, Afyx, Aobiome, Arena Pharmaceuticals, Asana Biosciences, Aslan Pharmaceuticals, BioMX, Biosion, Bluefin, Bodewell, Boehringer Ingelheim, Cara Therapeutics, Castle Biosciences, Celgene, Connect Biopharma, Dermavant, Dermira, Dermtech, Eli Lilly & Co, Galderma, GlaxoSmithKline, Incyte, Kiniksa, LEO Pharma, Luna, Menlo, Novartis, Optum, Pfizer, RAPT Therapeutics, Regeneron, Sanofi-Genzyme, Shaperon, Sidekick Health, Union Therapeutics; and received institutional grants from Galderma and Pfizer. E. Guttman-Yassky is an employee at Mount Sinai; received research funds (grants paid to the institution) from Amgen, AnaptysBio, Asana Biosciences, AstraZeneca, Boehringer Ingelheim, Cara Therapeutics, Celgene, Eli Lilly & Co, Innovaderm, Kyowa Kirin, LEO Pharma, Novartis, Pfizer, and Regeneron; and is a consultant for AbbVie, Almirall, Amgen, Arena Pharmaceuticals, Asana Biosciences, Aslan Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Meyers Squibb, Cara Therapeutics, Celgene, Connect Pharma, Eli Lilly & Co, EMD Serono, Evidera, Galderma, Ichnos Sciences, Incyte, Janssen Biotech, Kyowa Kirin, LEO Pharma, Pandion Therapeutics, Pfizer, RAPT Therapeutics, Regeneron, Sanofi-Genzyme, SATO Pharmaceutical, Siolta Therapeutics, Target Pharma Solutions, UCB, and Ventyx Biosciences. |
Vol 151 - N° 5
P. 1155-1162 - Maggio 2023 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?